In this issue:
Cytogenetics and long-term survival in IFM 99
Bortezomib/bendamustine/ prednisone in MM with renal failure
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combinations
Induction/maintenance plus bisphosphonates and bone disease in MM
Cyclophosphamide vs. melphalan regimen in elderly
MM with renal impairment
Syncopated thalidomide, lenalidomide in MM
Bortezomib + high-dose melphalan in resistant myeloma
MM in octogenarians
VTD vs. TD after transplant in newly diagnosed MM
VCD ±thalidomide in relapsed/refractory MM
Please login below to download this issue (PDF)